- Trial phase
- Phase 2 (completed)
- Time to market
- Phase 3 has not yet begun (planned for 2027). If Phase 3 succeeds, potential FDA submission would be several years away, likely 2029-2030 at the earliest.
- Why 3/10
- Dazucorilant is a Phase 2-stage asset with no hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The next catalyst is the planned Phase 3 trial initiation in 2027, which is a soft timeline event, not a binary outcome. The drug is one of several pipeline programs at a commercial-stage company whose main near-term value driver is the relacorilant PDUFA on December 17, 2026.
Dazucorilant's next catalyst is the planned Phase 3 trial initiation, expected in 2027 per the Q3 2026 earnings call. There is no PDUFA or binary readout date on the calendar for this drug within the next 12 months. The main near-term value driver for Corcept is the relacorilant PDUFA for Cushing's syndrome on December 17, 2026, not dazucorilant. Investors should watch for Phase 3 trial design details and enrollment timelines as the next meaningful derisking event.
Price Chart
Executive Summary
Dazucorilant (CORT-113176) is an oral, brain-penetrant selective glucocorticoid receptor modulator being developed by Corcept Therapeutics (NASDAQ: CORT) primarily for amyotrophic lateral sclerosis (ALS). In the Phase 2 DAZALS study (249 patients), the drug failed its primary endpoint of slowing disease progression but showed a striking 87% reduction in risk of death at two years for the 300 mg dose versus placebo. The FDA has granted Fast Track Designation. Corcept plans to initiate a pivotal Phase 3 trial in 2027, per the company's Q3 2026 earnings call. Dazucorilant is an early-stage pipeline asset at a profitable commercial-stage company; the survival signal is compelling but unconfirmed, and there is no near-term binary catalyst for this drug specifically. The stock's main near-term catalyst is the relacorilant PDUFA for Cushing's syndrome on December 17, 2026.
How It Works
Dazucorilant is an oral pill that blocks the effects of cortisol, a stress hormone, by binding to its receptor (the glucocorticoid receptor). In neurodegenerative diseases like ALS, elevated cortisol is thought to contribute to nerve cell damage and inflammation. By modulating cortisol activity, dazucorilant aims to reduce neuroinflammation and slow disease progression. It is designed to cross into the brain (brain-penetrant), which is important for treating neurological conditions.
Trial Status
The Phase 2 DAZALS study (NCT05407324) randomized 249 ALS patients to 150 mg, 300 mg, or placebo daily for 24 weeks. The primary endpoint (change in ALSFRS-R score) was not met. However, a secondary analysis showed the 300 mg dose reduced the risk of death by 87% over two years versus placebo. An open-label extension is ongoing. Corcept plans to initiate a Phase 3 trial in 2027, with overall survival as the primary endpoint.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 trial initiation expected in 2027 (no specific date announced)
- Any FDA feedback on Phase 3 trial design following Fast Track interactions
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report